October 8: Moderna & MiNA Therapeutics

October 8: Moderna & MiNA Therapeutics

by Alicia Bicknell, PhD

Life & Natural Systems Engineering & Technology TCBiochemical engineeringTCBBiotechnology
🎙 Alicia Bicknell, PhD 👥 2K 📅 October 9, 2025 ⏱ 29 min 👁 376 📄 original study 🧭 2026-08-16
Available in: English (current) Français

Keywords

mRNA degradationdeadenylation3' inverted deoxythymidineribosome densityinitiation rate

Summary

In this seminar, Dr. Alicia Bicknell presents her work at Moderna on improving mRNA therapeutics by stabilizing the 3’ end against deadenylation. She describes two mRNA pools designed to study degradation mechanisms: one with varying coding sequence design and another with different encoded proteins. Using RNA sequencing and nanopore technology, they measured RNA half-lives and deadenylation rates, finding that deadenylation is a key determinant of mRNA stability. They developed a 3’ inverted deoxythymidine (IDT) modification that inhibits deadenylation in vitro and extends RNA half-life and protein expression in cells and in vivo. The talk also explores the relationship between translation and deadenylation, showing that ribosome density correlates with deadenylation rate, and that initiation rate, influenced by secondary structure near the start codon or RNA length, is a major factor. The IDT modification is most beneficial for mRNAs with high deadenylation rates. The presentation concludes with a Q&A session addressing potential mechanisms of residual degradation and the structural basis of IDT.

160 words

Critical Evaluation

Value of the Information & Strength of the Argument

The talk provides valuable insights into mRNA degradation mechanisms and a practical solution to improve mRNA therapeutics. The argumentation is solid, based on systematic experiments with two well-designed mRNA pools. The correlation between deadenylation rate and RNA half-life is convincingly demonstrated, and the IDT modification is shown to be effective. The discussion of translation’s role in deadenylation is well-supported by ribosome profiling and initiation rate measurements. However, some aspects, such as the exact mechanism of residual degradation, remain unresolved, and the presentation is limited to one speaker’s work.

Scientific Rigor, Source Quality, Title Accuracy

The scientific rigor is high, with detailed experimental methods and data. The sources cited are primarily the speaker’s own work and collaboration with Eugene Valkov’s lab, but no specific publications are mentioned. The title is accurate but incomplete, as it omits the fact that only the Moderna talk is shown. The content is well-structured and technically sound, but the lack of peer-reviewed references and the limited public availability of the full data slightly reduce the reliability score.

180 words

Title / Content Match

The title is accurate but incomplete; it mentions both Moderna and MiNA Therapeutics, but only the Moderna talk is shown.

Quality & Reliability

8/10

The talk presents original research from a scientist at Moderna, with detailed methodology and data. The findings are plausible and align with known mechanisms of mRNA degradation, but the lack of peer-reviewed publication details and the limited public availability of the full data reduce the score.

Key Moments

Markers derived by PSI from the transcript: the creator did not define chapters.

Cited Sources

  • Moderna Therapeutics — The speaker's former employer and the context of the research.
  • Eugene Valkov Lab at NCI — Collaboration for in vitro deadenylation assays.

Concurring Sources

Contribution & Novelties

The talk presents a novel 3’ inverted deoxythymidine (IDT) modification that stabilizes mRNA against deadenylation, extending half-life and protein expression. It also provides insights into the relationship between translation and deadenylation, showing that initiation rate is a key determinant. This work could improve the potency and duration of mRNA therapeutics.

Pour aller plus loin :

  • mRNA degradation pathways — Overview of mRNA decay mechanisms.
  • Deadenylation — Detailed description of the deadenylation process.
  • mRNA therapeutics — Background on mRNA-based drugs.

79 words

Radar Profile

The radar profile shows high scores in information quantity, quality, and technical level, with slightly lower reliability due to the lack of peer-reviewed sources. The overall balance indicates a technically strong presentation with minor limitations in source verification.

Reliability 7/10

💬 No comments were provided for analysis.